Meeting ID: 938 2185 3236
Password: 852113
https://ucsf.zoom.us/j/93821853236?pwd=pIfJFanKpiBk7LY2N63B7w3oShOp8Q.1&from=addon
Carlo Hojilla, PhD, RN joined Virology Clinical Development at Gilead Sciences in 2021 after completing his PhD and postdoctoral training at UCSF. At Gilead, he led the PURPOSE 4 study as the medical monitor and later assumed responsibility for the pivotal PURPOSE 2 program, navigating the transition of that study to open label extension. The PURPOSE studies demonstrated the safety and high efficacy of twice-yearly subcutaneous lenacapavir for PrEP in diverse, underserved populations. Currently, Carlo oversees the Phase 4 lenacapavir for PrEP research portfolio as the HIV Prevention Team Lead and Director of Medical Affairs Research.
